RxDoctor Payments Data

Terry Roode, DO

Family Medicine · New Bremen, OHNPI 1093749913

Payments from drug & device makers

$979in general payments, 2019–2025

Across 61 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • Novo Nordisk$152
  • Lilly USA, LLC$148
  • Abbott$106
  • GSK$98
  • Amgen$49
  • plus $166 from 5 others

What the payments were for

  • Food & beverage$979100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)16$260
Novo Nordisk11$152
Lilly USA, LLC10$148
Abbott5$106
GSK5$98
Amgen3$49
Pfizer3$49
Novartis3$47
AstraZeneca3$40
Biohaven Pharmaceutical Holding Company Ltd.1$17
Merck1$13

How this compares

$979 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$85,343
Medicare patients
456
Services billed
17,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$116,245
EliquisApixaban89$97,204
MounjaroTirzepatide50$53,871
FarxigaDapagliflozin Propanediol35$42,048
XareltoRivaroxaban31$33,782
JanuviaSitagliptin Phosphate35$32,121
TrulicityDulaglutide26$26,074
Bydureon BciseExenatide Microspheres16$18,177
Repatha SureclickEvolocumab19$16,951
JardianceEmpagliflozin21$16,736
EntrestoSacubitril/Valsartan11$14,129
Tresiba Flextouch U-200Insulin Degludec19$12,488
MyrbetriqMirabegron18$10,294
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$10,156
Spiriva RespimatTiotropium Bromide15$8,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$116,245109 claims
PfizerEliquis$49$97,20489 claims
Lilly USA, LLCMounjaro, Trulicity$148$79,94576 claims
AstraZenecaFarxiga, Brilinta, Symbicort$40$52,07859 claims
MerckJanuvia$13$32,12135 claims
NovartisEntresto$47$14,12911 claims
GSKTrelegy Ellipta$98$8,27613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in New Bremen

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →